{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-008448","form_type":"8-K","ticker":"SPRB","cik":"0001683553","company_name":"SPRUCE BIOSCIENCES, INC.","filed_at":"2023-03-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.133094+00:00","generated_at":"2026-06-18T00:38:10.048369+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Spruce Biosciences reports FY2022 net loss $46.2M, cash $79.1M; pipeline updates","bullets":["Net loss $46.2M for FY2022 vs $42.3M in 2021; R&D expenses $35.2M, G&A $12.1M.","Cash, equivalents and investments $79.1M as of Dec 31, 2022; additional $53.6M private placement closed Feb 2023.","CAHmelia-203 in adult classic CAH surpassed 50% enrollment; topline data expected H2 2023.","Strategic partnership with Kaken Pharmaceutical for tildacerfont in Japan; $15M upfront received; cash runway into 1H 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-008448","json":"https://secwatch.observer/filing/0000950170-23-008448.json","markdown":"https://secwatch.observer/filing/0000950170-23-008448.md","text":"https://secwatch.observer/filing/0000950170-23-008448.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1683553/000095017023008448/0000950170-23-008448-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1683553/000095017023008448/sprb-20230316.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T00:38:10.048369+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2ab9d60662344c3eb70a5145c5e3aa17d733ef1c","claim":"SPRUCE BIOSCIENCES, INC. reported the year ended December 31, 2022 results: net income Net loss for the year ended December 31, 2022 was $46.2 million compared to $42.3 million in 2021..","evidence_excerpt":"Spruce Biosciences, Inc. (the \"Company\") issued a press release announcing its financial results for the full year ended December 31, 2022 and providing corporate updates.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1683553/000095017023008448/0000950170-23-008448-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2022"},{"label":"Net income","value":"Net loss for the year ended December 31, 2022 was $46.2 million compared to $42.3 million in 2021."},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}